FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1778-1787 December 14, 2000 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Influenza is a disease known since antiquity that continues to afflict large numbers of people and cause many deaths throughout the world. The annual epidemic and the continued threat of a pandemic constitute a major infectious-disease problem.^{1,2,3,4,5,6,7,8} Although the prevention of the spread of virus by ill persons and the removal of virus in transit in the environment could theoretically contribute to the control of influenza, effective control requires the optimal use of vaccines and antiviral drugs. At present, a vaccine and four antiviral drugs are approved in the United States and many other countries for the prevention and treatment . . . [Full Text of this Article]

Vaccines

Inactivated Vaccines

            Efficacy

            Adverse Effects

            Implementation

Live Attenuated Vaccine

Antiviral Drugs

Amantadine and Rimantadine

            Antiviral Action

            Pharmacokinetics

            Adverse Effects

            Efficacy

            Dosage

            Drug Resistance

Zanamivir and Oseltamivir

            Antiviral Action

            Pharmacokinetics

            Adverse Effects

            Efficacy

            Drug Resistance

Recommendations for Use of Antiviral Drugs

Selection of an Antiviral Drug

Long-Term Care Facilities

Conclusions

Source Information

From the Department of Molecular Virology and Microbiology and the Department of Medicine, Baylor College of Medicine, Houston. This article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Address reprint requests to Dr. Couch at the Department of Molecular Virology and Microbiology, 1 Baylor Plaza, Houston, TX 77030, or at rcouch@bcm.tmc.edu.

References

This article has been cited by other articles:

• Krief, W. I., Levine, D. A., Platt, S. L., Macias, C. G., Dayan, P. S., Zorc, J. J., Feffermann, N., Kuppermann, N., for the Multicenter RSV-SBI Study Group of the Ped, (2009). Influenza Virus Infection and the Risk of Serious Bacterial Infections in Young Febrile Infants. Pediatrics 124: 30-39 [Abstract] [Full Text]  
• Madjid, M., Miller, C. C., Zarubaev, V. V., Marinich, I. G., Kiselev, O. I., Lobzin, Y. V., Filippov, A. E., Casscells, S. W. III (2007). Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. Eur Heart J 28: 1205-1210 [Abstract] [Full Text]  
• Galvani, A. P., Reluga, T. C., Chapman, G. B. (2007). Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc. Natl. Acad. Sci. USA 104: 5692-5697 [Abstract] [Full Text]  
• Weinberg, A., Walker, M. L. (2005). Evaluation of Three Immunoassay Kits for Rapid Detection of Influenza Virus A and B. CVI 12: 367-370 [Abstract] [Full Text]  
• Smitherman, H. F., Caviness, A. C., Macias, C. G. (2005). Retrospective Review of Serious Bacterial Infections in Infants Who Are 0 to 36 Months of Age and Have Influenza A Infection. Pediatrics 115: 710-718 [Abstract] [Full Text]  
• Hindiyeh, M., Levy, V., Azar, R., Varsano, N., Regev, L., Shalev, Y., Grossman, Z., Mendelson, E. (2005). Evaluation of a Multiplex Real-Time Reverse Transcriptase PCR Assay for Detection and Differentiation of Influenza Viruses A and B during the 2001-2002 Influenza Season in Israel. J. Clin. Microbiol. 43: 589-595 [Abstract] [Full Text]  
• Jeon, S. H., Kayhan, B., Ben-Yedidia, T., Arnon, R. (2004). A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin. J. Biol. Chem. 279: 48410-48419 [Abstract] [Full Text]  
• Balicer, R. D, Huerta, M., Grotto, I. (2004). Tackling the next influenza pandemic. BMJ 328: 1391-1392 [Full Text]  
• McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L. (2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI 11: 21-28 [Abstract] [Full Text]  
• Gaglani, M. J., Herschler, G. B. (2004). Every Nose Counts: A New Influenza Vaccine for All Healthy Schoolchildren?. CLIN PEDIATR 43: 35-41 [Abstract]  
• Habib-Bein, N. F., Beckwith, W. H. III, Mayo, D., Landry, M. L. (2003). Comparison of SmartCycler Real-Time Reverse Transcription-PCR Assay in a Public Health Laboratory with Direct Immunofluorescence and Cell Culture Assays in a Medical Center for Detection of Influenza A Virus. J. Clin. Microbiol. 41: 3597-3601 [Abstract] [Full Text]  
• Halperin, S. A., Smith, B., Nolan, C., Shay, J., Kralovec, J. (2003). Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial. CMAJ 169: 111-117 [Abstract] [Full Text]  
• (2002). {blacktriangledown}Oseltamivir for influenza. DTB 40: 89-91 [Abstract] [Full Text]  
• Rennels, M. B., Meissner, H. C., Committee on Infectious Diseases, (2002). Technical Report: Reduction of the Influenza Burden in Children. Pediatrics 110: e80-e80 [Abstract] [Full Text]  
• Tumpey, T. M., Garcia-Sastre, A., Mikulasova, A., Taubenberger, J. K., Swayne, D. E., Palese, P., Basler, C. F. (2002). Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA 99: 13849-13854 [Abstract] [Full Text]  
• Ahmed, F., Singleton, J. A., Franks, A. L. (2001). Influenza Vaccination for Healthy Young Adults. NEJM 345: 1543-1547 [Full Text]  
• Haley, C. E (2001). Postexposure prophylaxis with inhaled zanamivir was efficacious for household contacts of people with influenza. Evid. Based Med. 6: 140-140 [Full Text]  
• Haley, C. E (2001). Oseltamivir reduced new cases of influenza in household contacts of people with clinical or confirmed influenza. Evid. Based Med. 6: 141-141 [Full Text]  
• Drusano, G. L., Preston, S. L., Smee, D., Bush, K., Bailey, K., Sidwell, R. W. (2001). Pharmacodynamic Evaluation of RWJ-270201, a Novel Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts Efficacy for Once-Daily Dosing. Antimicrob. Agents Chemother. 45: 2115-2118 [Abstract] [Full Text]  
• Coonrod, J. D. (2001). Influenza : Will New Diagnostic Tests and Antiviral Drugs Make a Difference?. Chest 119: 1630-1632 [Full Text]